New Data, New Directions: Neladalkib (NVL-655) and Precision Oncology in ALK-Positive Cancer

Alexander Drilon, MD, is a thoracic oncologist and Chief of the Early Drug Development Service at Memorial Sloan Kettering Cancer Center, with research focused on ALK-positive cancers.

In this ALKtALK, Dr. Drilon discusses the latest clinical data on neladalkib (NVL-655). The conversation explores emerging efficacy and safety findings and provides insight into how promising therapies move from clinical trials toward broader patient access. Dr. Drilon also shares perspective from his ongoing research, highlighting how translational science and biomarker-driven approaches continue to shape treatment strategies in ALK-positive lung cancer.

This data-driven discussion focuses on where the science stands today—and where it may be headed next for patients and families navigating ALK-positive disease. The recording includes audience questions from the live session, offering additional context and practical insight.

Whether you are newly diagnosed, currently in treatment, exploring clinical trials, or supporting someone you love, this ALKtALK is designed to help you stay informed and connected to the research shaping our community.

Subscribe to the ALK Positive YouTube channel for future ALKtALK recordings and research updates.

+ + + About our ALKtALKs and ALK Positive Inc + + +

ALK Positive does not endorse specific treatments and does not provide medical advice. Questions and concerns should be raised with individual care teams.

ALK Positive is a 501(c)(3)-registered, patient-driven organization that seeks a cure for ALK+ cancer and works to improve patients’ quality of life and life expectancy worldwide. ALK Positive is committed to raising funds for research proposals that will transform ALK-positive cancer into a chronic or curable condition for all patients living with this disease.

We offer a full range of Healing Arts classes to help our community balance a productive life, treatment side effects and the mental stress of a cancer diagnosis. These include ALKtALKs -- our flagship community program aimed at making our ALK community a little smarter and a little smaller, by bringing the latest information, research and practices from leading experts.

For more information about us, go to www.alkpositive.org.

To donate 💖 go to https://www.alkpositive.org/ways-to-give

📢 Follow us on social media & join the conversation online!

Facebook 📘 / alkpositivecancer
Instagram 📸 / alkpositiveinc
LinkedIn 💼 / alkpositivecancer
X (Twitter) ✖️ https://x.com/ALKPositiveinc
TikTok 🎵 / alkpositiveinc
BlueSky ☁️ https://bsky.app/profile/alkpositive....

Видео New Data, New Directions: Neladalkib (NVL-655) and Precision Oncology in ALK-Positive Cancer канала ALK Positive Inc.